AGY
NEUTRALAllergy Therapeutics Announces New Board Appointments
The biotechnology company announces the appointment of two new directors to its board, bringing expertise in strategy and finance as it explores a potential dual listing.
Allergy Therapeutics
11.80GBX
-0.84%
Market Cap
724.69M
Volume
338.42k
80% of avg
P/E Ratio
-1638.89
EPS (TTM)
-0.01
Beta
0.81
Day Range
11.00p - 11.90p
52 Week Range
5.00p11.80p12.00p
11.80p
Upcoming Events
AGY
GOODAllergy Therapeutics Granted Marketing Authorisation for Grassmuno® in Germany
The biotechnology company has received marketing authorisation for its grass pollen allergy treatment in Germany, marking a key milestone in its expansion strategy.
AGY
NEUTRALAllergy Therapeutics Seeks Shareholder Approval for Potential Equity Raise
The biotechnology company is seeking shareholder approval to issue up to 610 million new shares to facilitate a potential equity raise, ahead of a planned dual listing on the Hong Kong Stock Exchange.
AGY
BADAllergy Therapeutics Reports Flat Revenue and Increased Losses Amid Market Challenges
The pharmaceutical firm reported flat revenue and increased losses amidst regulatory changes in key markets. Despite progress in clinical trials, financial challenges and market headwinds persist.
AGY
NEUTRALAllergy Therapeutics Provides Update on PROTECT Trial for VLP Peanut
The biotechnology company announces that its PROTECT trial has completed final dosing of the minimum required number of patients at the highest planned treatment dose, meeting the trial's primary safety endpoint.
AGY
NEUTRALAllergy Therapeutics Explores Dual Listing on HKEX
The biotechnology company is considering a dual listing of its shares on the Hong Kong Stock Exchange, aiming to expand its presence in Asia and broaden its investor base.
AGY
NEUTRALAllergy Therapeutics Advances Grass MATA MPL Paediatric Trial to Second Year
The biotechnology company has commenced patient screening for the second year of its Phase III trial evaluating the long-term efficacy and safety of its Grass MATA MPL product in paediatric subjects.
AGY
GOODAllergy Therapeutics Strengthens Balance Sheet with Warrant Exercise and New Loan Facility
The biotechnology company has exercised existing warrants, repaying its shareholder debt and securing a new loan facility to strengthen its balance sheet and financial flexibility.
AGY
NEUTRALAllergy Therapeutics Provides Update on Peanut Allergy Vaccine Trial
The biotechnology company reports further positive progress in its clinical trial evaluating the safety and tolerability of a short-course peanut allergy vaccine.
AGY
NEUTRALAllergy Therapeutics Publishes Positive Data on Grass MATA MPL in Allergy Journal
The biotechnology company announces the publication of three papers in a leading allergy journal that strengthen the evidence base for its Grass MATA MPL allergen immunotherapy.